Alzamend Neuro, Inc. (Nasdaq:ALZN) is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”), and post-traumatic stress disorder (“PTSD”), announced today that it has received a written response to its meeting request related to its Type B Pre-Investigational New Drug (“IND”) Alzamend’s planned clinical development of AL001 for the treatment of bipolar disorder, MDD, and PTSD is enabled by the FDA’s response. AL001 is a novel lithium-delivery system; particularly, it is an engineered lithium-salicylate-L-proline ionic mendcocrystal being developed as an oral treatment for Alzheimer’s-related ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap . Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here .
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer .
For further details see:
FDA provides a positive pre-IND response to Alzamend Neuro for AL001.